The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Abstract Each year, about 5–6 cases out of 100,000 people are diagnosed with primary
malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma …

We tested the interaction of 72 kinase inhibitors with 442 kinases covering> 80% of the
human catalytic protein kinome. Our data show that, as a class, type II inhibitors are more …

The RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the regulation of
proliferation, differentiation and survival. The induction of these pathways depends on …

Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of
cancer. Genetic and biochemical data have demonstrated that the growth and motility factor …

The MET pathway is dysregulated in many human cancers and promotes tumour growth,
invasion and dissemination. Abnormalities in MET signalling have been reported to …

The HGF/MET signaling pathway is critical in mediating a wide range of normal
physiological functions including embryological development, wound healing, and tissue …

In addition to each of the factors that govern the identification of a successful oncology drug
candidate, drug discovery aimed at treating neurological cancer must also consider the …

Purpose: The mesenchymal–epithelial transition factor (c-Met) receptor, also known as
hepatocyte growth factor receptor (HGFR), controls morphogenesis, a process that is …

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the
invention of a series of novel triazolopyrazine c-Met inhibitors. The structure–activity …